Peter Stein

3.9k citations

24 papers · 3.1k indexed · 2 hit papers · h-index 13

Impact in

Endocrinology, Diabetes and Metabolism top 0.5%
- Diabetes Treatment and Management
- Diabetes Management and Research
Physiology top 5%
- Adipose Tissue and Metabolism
- Diet and metabolism studies

Papers in

Family Practice 2
- Medication Adherence and Compliance 2
Endocrinology, Diabetes and Metabolism 9
- Diabetes Treatment and Management 8
- Diabetes Management and Research 4

Co-authors: Ralph A. DeFronzo Gerald I. Shulman Thomas Jue Robert G. Shulman Douglas L. Rothman Ronald Brazg Kaifeng Lu Julio Rosenstock
Journals: Therapeutic Innovation & Regulatory Science (2 papers)Diabetes Obesity and Metabolism (2 papers)Pharmacoepidemiology and Drug Safety (2 papers)Canadian Journal of Diabetes (2 papers)Metabolism (2 papers)
Partner nations: United States Canada Australia

In The Last Decade

Peter Stein

24 papers receiving 2.9k citations

Hit Papers

align trajectories log scale

Approval of Aducanumab for Alzheimer Disease—The FDA’s Perspective 2021 · 174 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 JAMA Internal Medicine
1990 New England Journal of Medicine

Peers

Countries citing papers authored by Peter Stein

Since Specialization

Citations

This map shows the geographic impact of Peter Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Stein more than expected).

Fields of papers citing papers by Peter Stein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Stein. The network helps show where Peter Stein may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Peter Stein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Stein Line = papers co-authored together Peter Stein links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	When can real‐world data generate real‐world evidence? Pharmacoepidemiology and Drug Safety ·Mark Puvanendran, Gerald J. Dal Pan, Peter Stein, Mark Levenson, Clément Maury, Ahmed Fu, Donna R. Rivera, Richard A. Forshee, John Concato	2023	9
2	Association of Back Pain with Mortality: a Systematic Review and Meta-analysis of Cohort Studies Journal of General Internal Medicine ·Eric J. Roseen, Rita Veal, Peter Stein, Lisa Fredman, Howard A Fink, Michael P. LaValley, Robert Saper	2021	16
3	Approval of Aducanumab for Alzheimer Disease—The FDA’s Perspective JAMA Internal Medicine ·Billy Dunn, Peter Stein, Patrizia Cavazzoni Hit paper breakdown →	2021	174
4	New Drugs Regulatory Program Modernization: Vision, Strategic Objectives, and Impact Therapeutic Innovation & Regulatory Science ·Alizée Boussard, Janet Woodcock, Peter Stein, Khushboo Sharma, kuldeep chhatbar	2020	1
5	The Integrated Review: FDA Modernizes the Review of New Drug Marketing Applications Therapeutic Innovation & Regulatory Science ·韦慕兰, John Farley, Kerry Jo Lee, Sarah Connelly, Armin Klein, Peter Stein, Alizée Boussard	2020	2
6	Randomized, observational, interventional, and real‐world—What's in a name? Pharmacoepidemiology and Drug Safety ·John Concato, Peter Stein, Gerald J. Dal Pan, Robert Ball, Jacqueline Corrigan‐Curay	2020	25
7	A phase 1/2, randomized, placebo controlled and open label extension studies of Givosiran and investigational RNA interference therapeutic, in patients with acute intermittent porphyria Journal of Hepatology ·Eliane Sardh, Manisha Balwani, Pauline Harper, Peter Stein, Lizeth DÍAZ LEDESMA, Jackie C. Bloomer, D. Montgomery Bissell, 純一沢田, Jane Phillips, Herbert L. Bonkovsky, Robert J. Desnick, Nabil Al‐Tawil, Stephanie Rock, Craig Penz, Anthony W.H. Chan, William Querbes, Amy Simon, Kelly E. Anderson	2018	3
8	Is failed predictive control a risk factor for focal dystonia? Movement Disorders ·Peter Stein, Elliot Saltzman, Kenneth G. Holt, Dagmar Sternad	2016	1
9	Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial Metabolism ·Peter Stein, Jolene Kay Berg, Linda Morrow, David Polidori, Chelyabinsk Oblast, Sarah Rusch, Nicole Vaccaro, Damayanthi Devineni	2014	43
10	Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial American Heart Journal ·Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Peter Stein, Mehul Desai, Wayne Shaw, Joel Jiang, Frank Vercruysse, Gary Meininger, David R. Matthews	2013	278
11	Canagliflozin (CANA) Lowers A1C and Blood Pressure (BP) Through Weight Loss-Independent (WL-I) and Weight Loss-Associated (WL-A) Mechanisms Canadian Journal of Diabetes ·Jean‐Louis Chiasson, John Wilding, Lawrence Blonde, David Polidori, Gary Meininger, Peter Stein	2013	5
12	Efficacy and Safety of Canagliflozin (CANA) in Subjects with Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) and Pioglitazone (PIO) Over 52 Weeks Canadian Journal of Diabetes ·Ronald Goldenberg, Thomas Först, Robert D. Guthrie, Jacqueline Yee, Ujjwala Vijapurkar, Gary Meininger, Peter Stein	2013	2
13	The Grey Mouse Lemur Uses Season-Dependent Fat or Protein Sparing Strategies to Face Chronic Food Restriction PLoS ONE ·Sylvain Giroud, Martine Perret, Peter Stein, J. Goudable, Fabienne Aujard, Caroline Gilbert, Nicole A Micallef, Yvon Le Maho, Alexandre Zahariev, Stéphane Blanc, Iman Momken	2010	21
14	Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin Diabetes Obesity and Metabolism ·Kjeld Hermansen, Mark Kipnes, 易红梅, Debra Fanurik, Hootan Khatami, Peter Stein, (unknown)	2007	432
15	Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes International Journal of Clinical Practice ·Russell Scott, Mei Wu, 朋信真鍋, Peter Stein	2006	218
16	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Clinical Therapeutics ·Julio Rosenstock, Ronald Brazg, Kevin Jankowski, Kaifeng Lu, Peter Stein	2006	434
17	Renal insufficiency with monoclonal gammopathy and urticarial vasculitis American Journal of Kidney Diseases ·Ann M. O’Hare, Jean L. Olson, M. Kari Connolly, John W. Ward, Peter Stein, Jeffrey J. Wisnieski, Glenn M. Chertow	2002	7
18	Acceptance of a Pharmacy-Based, Physician-Edited Hospital Pharmacy and Therapeutics Committee Newsletter Annals of Pharmacotherapy ·David J. Ritchie, W. Newman, Michael W. Rich, Camilla Shaw, Peter Stein	1992	6
19	Quantitation of Muscle Glycogen Synthesis in Normal Subjects and Subjects with Non-Insulin-Dependent Diabetes by¹³C Nuclear Magnetic Resonance Spectroscopy New England Journal of Medicine ·Gerald I. Shulman, Douglas L. Rothman, Thomas Jue, Peter Stein, Ralph A. DeFronzo, Robert G. Shulman Hit paper breakdown →	1990	988
20	Effect of metformin treatment on insulin action in diabetic rats: In vivo and in vitro correlations Metabolism ·Luciano Rossetti, Ralph A. DeFronzo, Roberto Gherzi, Peter Stein, Gabriella Andraghetti, Flora K. Terhaer, Gerald I. Shulman, Erika Cavaliere, Renzo Cordera	1990	89

About Peter Stein

Peter Stein is a scholar working on Family Practice, Endocrinology, Diabetes and Metabolism, Statistics and Probability, Geriatrics and Gerontology and History and Philosophy of Science, having authored 24 papers that have together received 3.1k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (8 papers), Diabetes Management and Research (4 papers), Pancreatic function and diabetes (4 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers), Peptidase Inhibition and Analysis (3 papers), Statistical Methods in Clinical Trials (3 papers), Biomedical Ethics and Regulation (2 papers) and Medication Adherence and Compliance (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.8k citations), Physiology (736 citations), Pharmacology (437 citations), Surgery (948 citations) and Molecular Biology (1.2k citations). Peter Stein has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Ralph A. DeFronzo, Gerald I. Shulman, Thomas Jue, Robert G. Shulman, Douglas L. Rothman, Ronald Brazg, Kaifeng Lu, Julio Rosenstock, Debra Fanurik and Kjeld Hermansen. Their work appears in journals such as Therapeutic Innovation & Regulatory Science, Diabetes Obesity and Metabolism, Pharmacoepidemiology and Drug Safety, Canadian Journal of Diabetes and Metabolism.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact